| sCoV (N = 190) | COVID-19 (N = 190) | P-value |
---|---|---|---|
Steroids | 86 (45.3%) | 83 (43.7%) | .757 |
Antibiotics | 182 (95.8%) | 175 (92.1%) | .132 |
Maximal respiratory support on presentation | Â | Â | .032 |
 None | 56 (29.5%) | 56 (29.5%) |  |
 Nasal cannula | 95 (50%) | 111 (58.4%) |  |
 NIV | 25 (13.2%) | 9 (4.7%) | .004b |
 IMV | 14 (7.4%) | 14 (7.4%) |  |
Prone position | 2 (1.1%) | 21 (11.1%) |  < .001 |
Neuromuscular blockade | 1 (0.5%) | 34 (17.9%) |  < .001 |
Vasopressors | 19 (10%) | 32 (16.8%) | .050 |
Respiratory failure | 134 (70.5%) | 135 (71.1%) | .910 |
Sepsis | Â | Â | Â |
 SIRS | 124 (65.3%) | 120 (63.2%) | .669 |
 qSOFA | 39 (20.5%) | 69 (36.3%) | .001 |
 Septic shock | 27 (14.2%) | 38 (20%) | .134 |
ARDS | 6 (2.6%) | 38 (15.8%) |  < .001 |
Acute kidney injury | 48 (25.3%) | 84 (44.2%) |  < .001 |
Troponin leak | 49 (25.8%) | 55 (29.9%) | .373 |
Coinfection | 49 (25.8%) | 25 (13.2%) | .002 |
NIH severity | Â | Â | Â |
 Mild | 14 (7.4%) | 8 (4.2%) | .188 |
 Moderate | 47 (24.7%) | 33 (17.4%) | .078 |
 Severe | 129 (67.9%) | 149 (78.4%) | .021 |
Time from symptom onset to admission (days)a | 3 (1–7) | 2 (1–6) | .916 |
Hospital length of stay (days)a | 5 (3–8) | 7 (4–12) | .013 |
ICU admission | 67 (35.3%) | 61 (32.1%) | .515 |
IMV in total | 27 (14.2%) | 37 (19.5%) | .170 |
Successfully extubated | 16/27 (59.3%) | 13/37 (35.1%) | 0.056 |
Successfully discharged from ICU | 46/67 (73%) | 26/61 (43.3%) | 0.001 |
Onset to discharge (days)a | 9 (6–13.75) | 9.5 (7–16.75) | 0.902 |
Onset to death (days)a | 9 (5.75–15.25) | 10 (6.75–16.25) | 0.855 |
Case fatality rate | 22 (11.6%) | 66 (34.7%) | < .001 |